“ I’ve been to an earlier version of this at Bletchley Park, and that one was more focused on safety,” OpenAI CEO Sam Altman told Bloomberg TV during the summit. “People are now saying ‘Okay, this ...

My message to the leaders assembling here in Munich is clear: global health security will never be a zero-sum game.

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

Biotechnology Market SNS Insider Reports 13.29% CAGR Growth in Biotechnology Sector, Fueled by Healthcare, Agriculture, and Government Fund ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...

While people, technology, and processes are crucial to enhancing cybersecurity, no individual or organization can have ...

Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...

Experts at the 2025 Clinical Trial Supply Europe conference will explore supply chain challenges and the impact of AI on ...

GMG, a global retailer, manufacturer and distributor, has established itself as a dominant force in the retail industry ...